Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.43
-0.0289-0.09%
Volume:4K
Turnover:120.89K
Market Cap:41.35M
PE:- -
High:32.54
Open:32.54
Low:32.29
Close:32.46
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:1.09
T/O Rate:0.29%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
1 hour ago

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
1 hour ago

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Reuters
·
2 hours ago

Nurix Extends Gilead Collaboration for Oncology Program

Reuters
·
2 hours ago

Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026

THOMSON REUTERS
·
2 hours ago

Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties

THOMSON REUTERS
·
2 hours ago

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS
·
2 hours ago

Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs

THOMSON REUTERS
·
2 hours ago

Coursera, PSEG, Nauticus, Legend, Arlo Insider Shock

TIPRANKS
·
Oct 03

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares

Reuters
·
Oct 03

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Legend Biotech (LEGN)

TIPRANKS
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02